Effects of the Type 2 Diabetes-AssociatedPPARGP12A Polymorphism on Progression to Diabetes and Response to Troglitazone | Zendy

José C. Florez | Zendy; Kathleen A. Jablonski | Zendy; Maria Sun | Zendy; Nick Bayley | Zendy; Steven E. Kahn | Zendy; Harry Shamoon | Zendy; Richard F. Hamman | Zendy; William C. Knowler | Zendy; David M. Nathan | Zendy; David Altshuler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Effects of the Type 2 Diabetes-AssociatedPPARGP12A Polymorphism on Progression to Diabetes and Response to Troglitazone

Author(s) -

José C. Florez,

Kathleen A. Jablonski,

Maria Sun,

Nick Bayley,

Steven E. Kahn,

Harry Shamoon,

Richard F. Hamman,

William C. Knowler,

David M. Nathan,

David Altshuler

Publication year - 2007

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2006-2275

Subject(s) - peroxisome proliferator activated receptor gamma , troglitazone , medicine , type 2 diabetes , endocrinology , diabetes mellitus , body mass index , hazard ratio , confidence interval , peroxisome proliferator activated receptor , receptor

The common P12A polymorphism in PPARG (a target for thiazolidinedione medications) has been consistently associated with type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research